Regorafenib, an inhibitor of VEGF that targets multiple VEGF and PDGF receptors, demonstrated a significant improvement in PFS (7.4 vs. 5.6 months) compared to lomustine (another alkylating chemotherapeutic used to treat brain tumors) in patients with recurrent GBM in an initial study (NTC02926222) [129]. Here, VEGFA is linked to brain neoplasm.